Medically reviewed by Corinne Savides Happel, MD Hereditary angioedema (HAE) is a genetic disorder that causes episodes of ...

Discover the symptoms, causes and treatments for hereditary angioedema, a rare genetic disorder causing severe swelling that ...

Further information Decision makers have concluded that this technology will not progress as a potential technology appraisal or a highly specialised technology. This decision follows consideration of ...

HAE is a genetic disease marked by low levels or dysfunction of the C1 inhibitor. Patients can be struck with bouts of severe swelling across the body, and attacks can be fatal if they impact the ...

and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that the European Commission (EC) has granted orphan designation to its investigational drug, deucrictibant ...

Laryngeal attacks carry a risk of asphyxiation, making untreated events potentially fatal.1 Hereditary angioedema with reduced C1 esterase inhibitor (C1-INH) function (HAE-C1-INH) is the most common, ...

Lev's Cinryze (C1 esterase inhibitor) should receive a decision from the FDA in October. Three other firms are seeking US approval for HAE drugs aimed at the acute market—Dyax, of Cambridge ...

The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST®, Joenja ...

Target enrollment achieved in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelinesEnrollment underway in ...